NCT06640075 Community Co-produced Action for Improved Access to Cervical Cancer Screening in Cameroon
| NCT ID | NCT06640075 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Prof. Patrick Petignat |
| Condition | Cervical Cancer Screening |
| Study Type | INTERVENTIONAL |
| Enrollment | 800 participants |
| Start Date | 2024-04-13 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 800 participants in total. It began in 2024-04-13 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background - The burden of cervical cancer is unequally distributed globally, with over 90% of deaths occurring in low- and middle-income countries (LMICs), mainly due to insufficient uptake of preventive measures such as screening. In 2020, the World Health Organization launched a global initiative for the worldwide elimination of cervical cancer as a public health issue, setting a target of 70% of women screened with a high-performance test. In Cameroon, this target is far from being reached, and rural communities are disproportionately affected by low uptake of screening services. Recently, a new cervical cancer screening program has launched in the Bafoussam Regional Hospital, in the capital of the Mifi Health District, as part of a larger research project. To develop a context-specific strategy improving access to screening for women living in rural areas of the district, the active participation of community members for the co-development and implementation of local strategies for cervical cancer screening may be key to improving population screening coverage. Objective - The aim of this study is to evaluate the use of community co-produced action (CCA) for the development and implementation of HPV-based cervical cancer screening strategies compared to a traditional hospital-based approach in rural areas of the Mifi Health District in Cameroon. Methods - Using a cluster-randomized study design, participatory workshops with community members will be led in 7 rural health areas assigned to the intervention arm, with the aim of codeveloping local strategies for HPV-based cervical cancer screening adapted to the setting. The co-produced strategies may include raising awareness among eligible women (aged 30-49 years, or 25-49 years if HIV-positive), as well as facilitating access to screening tests, results and follow-up. Women living in one of the 7 health areas assigned to the control arm will be invited by community health workers to undergo screening at the Bafoussam Regional Hospital. In both study arms, screened women will be included in the GENOVA study, a cervical cancer screening trial offering free-of- charge HPV testing followed by triage by visual inspection or genotyping for HPV-positive women, and free treatment according to triage results. CCA will be evaluated by assessing its effectiveness for screening uptake. Screening coverage among eligible women will be estimated during one year after implementation of screening strategies in both study arms, based on population statistics provided by the Mifi health district for each health area. Expected results - Developing context-sensitive solutions to cervical cancer screening through a community-based participatory approach in rural areas of the Mifi health district is expected to improve screening participation rate.
Eligibility Criteria
Inclusion Criteria: * Women aged 30-49 years old (25-49 years old if HIV-positive) * Residency in one of the 14 rural health areas of Mifi health district * Ability to give signed informed consent Exclusion Criteria: * known cervical cancer * symptoms compatible with cervical cancer * previous hysterectomy * terminal disease other than cervical cancer * cervical cancer screening test in the last 5 years (3 years if HIV-positive) * pregnancy at the time of screening * lack of discernment capacity
Contact & Investigator
Patrick Petignat, PD
PRINCIPAL INVESTIGATOR
University Hospital, Geneva
Frequently Asked Questions
Who can join the NCT06640075 clinical trial?
This trial is open to female participants only, aged 25 Years or older, up to 49 Years, studying Cervical Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06640075 currently recruiting?
Yes, NCT06640075 is actively recruiting participants. Contact the research team at ania.wisniak@hug.ch for enrollment information.
Where is the NCT06640075 trial being conducted?
This trial is being conducted at Bafoussam, Cameroon.
Who is sponsoring the NCT06640075 clinical trial?
NCT06640075 is sponsored by Prof. Patrick Petignat. The principal investigator is Patrick Petignat, PD at University Hospital, Geneva. The trial plans to enroll 800 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.